Skip to main content
Premium Trial:

Request an Annual Quote

ProteoMedix Taking Part in $1.7M Prostate Cancer Biomarker Project


NEW YORK (GenomeWeb) – ProteoMedix said this week that it is taking part in a research project for the development of a prognostic test for prostate cancer funded by CHF1.6 million ($1.7 million) from Switzerland's Commission for Technology and Innovation.

The goal of the project is to develop an immunoassay-based risk stratification test for predicting disease aggressiveness in patients with localized prostate cancer.

While globally roughly 900,000 men are diagnosed with prostate cancer annually, many early-stage cases are non-aggressive and may not require immediate treatment. Therefore, there is significant need for prognostic tools for determining prostate cancer aggressiveness in order to avoid overtreatment.

As part of the project, the consortium, which includes groups from the Swiss Federal Institute of Technology Zurich, University Hospital Zurich, and the University of Applied Science North Western Switzerland, will further validate the prognostic potential of ProteoMedix's proprietary biomarkers.